Generic Name: NORETHINDRONE 0.5mg, ETHINYL ESTRADIOL 0.035mg; NORETHINDRONE 0.75mg, ETHINYL ESTRADIOL 0.035mg; NORETHINDRONE 1mg, ETHINYL ESTRADIOL 0.035mg;
Dosage Form: tablets
Drug Class: Contraceptives Sex hormone combinations
Generic Name: NORETHINDRONE 0.5mg, ETHINYL ESTRADIOL 0.035mg; NORETHINDRONE 0.75mg, ETHINYL ESTRADIOL 0.035mg; NORETHINDRONE 1mg, ETHINYL ESTRADIOL 0.035mg;
Dosage Form: tablets
Drug Class: Contraceptives Sex hormone combinations
To achieve maximum contraceptive effectiveness, ALYACEN 7/7/7 and ALYACEN 1/35 tablets must be taken exactly as directed and at intervals not exceeding 24 hours. ALYACEN 7/7/7 and ALYACEN 1/35 tablets are available in a blister pack which is preset for a Sunday Start. Day 1 Start is also available.
When taking ALYACEN 7/7/7 and ALYACEN 1/35, the first "active" tablet should be taken on the first Sunday after menstruation begins. If the period begins on Sunday, the first "active" tablet should be taken that day. Take one active tablet daily for 21 days followed by one light green "reminder" tablet daily for 7 days. After 28 tablets have been taken, a new course is started the next day (Sunday). For the first cycle of a Sunday Start regimen, another method of contraception such as a condom or spermicide should be used until after the first 7 consecutive days of administration.
If the patient misses one (1) "active" tablet in Weeks 1, 2, or 3, the tablet should be taken as soon as she remembers. If the patient misses two (2) "active" tablets in Week 1 or Week 2, the patient should take two (2) tablets the day she remembers and two (2) tablets the next day; and then continue taking one (1) tablet a day until she finishes the pack. The patient should be instructed to use a back-up method of birth control such as a condom or spermicide if she has sex in the seven (7) days after missing pills. If the patient misses two (2) "active" tablets in the third week or misses three (3) or more "active" tablets in a row, the patient should continue taking one tablet every day until Sunday. On Sunday the patient should throw out the rest of the pack and start a new pack that same day. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills.
Complete instructions to facilitate patient counseling on proper pill usage may be found in the Detailed Patient Labeling ("How to Take the Pill" section).
The dosage of ALYACEN 7/7/7 or ALYACEN 1/35, for the initial cycle of therapy, is one "active" tablet administered daily from the 1st through the 21st day of the menstrual cycle, counting the first day of menstrual flow as "Day 1" followed by one light green "reminder" tablet daily for 7 days. Tablets are taken without interruption for 28 days. After 28 tablets have been taken, a new course is started the next day.
If the patient misses one (1) "active" tablet in Weeks 1, 2, or 3, the tablet should be taken as soon as she remembers. If the patient misses two (2) "active" tablets in Week 1 or Week 2, the patient should take two (2) tablets the day she remembers and two (2) tablets the next day; and then continue taking one (1) tablet a day until she finishes the pack. The patient should be instructed to use a back-up method of birth control such as a condom or spermicide if she has sex in the seven (7) days after missing pills. If the patient misses two (2) "active" tablets in the third week or misses three (3) or more "active" tablets in a row, the patient should throw out the rest of the pack and start a new pack that same day. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills.
Complete instructions to facilitate patient counseling on proper pill usage may be found in the Detailed Patient Labeling ("How to Take the Pill" section).
The use of ALYACEN 7/7/7 or ALYACEN 1/35 for contraception may be initiated 4 weeks postpartum in women who elect not to breastfeed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered. (See CONTRAINDICATIONS and WARNINGS concerning thromboembolic disease. See also PRECAUTIONS: Nursing Mothers.) The possibility of ovulation and conception prior to initiation of medication should be considered.
(See Discussion of Dose-Related Risk of Vascular Disease from Oral Contraceptives.)